Cynata Therapeutics Limited (AU:CYP) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Cynata Therapeutics Limited, an Australian biotech firm, is set to present its innovative cell therapy for diabetic foot ulcers at the prestigious ISCT ANZ 2024 Regional Meeting in New Zealand. The company’s CEO, Dr. Kilian Kelly, will showcase the Cymerus™ iPSC-derived MSC topical wound dressing product candidate, CYP-006TK, highlighting its clinical development milestones. Cynata’s participation underscores its role in advancing cell therapeutics and its commitment to delivering novel treatments for various diseases including GvHD, osteoarthritis, and diabetic foot ulcers.
For further insights into AU:CYP stock, check out TipRanks’ Stock Analysis page.
